AddLife AB Class B (SE:ALIF.B)
:ALIF.B
Want to see SE:ALIF.B full AI Analyst Report?
Top Page
AddLife AB
(ALIF.B)
Select Model
Select Model
Rating:61Neutral
Price Target:
kr160.00
▲(3.16% Upside)
Action:ReiteratedDate:04/30/26
The score is driven primarily by stable financial quality (improving profitability and solid free cash flow) and a supportive earnings-call outlook (margin improvement and deleveraging). These positives are tempered by high valuation (P/E ~34.6, low yield) and a mixed technical setup with limited near-term momentum.
Positive Factors
Cash generation & conversion
Sustained strong operating and free cash flow gives AddLife durable self-funding capacity for capex, working-capital cushions and bolt-on M&A without heavy equity issuance. High cash conversion also supports deleveraging and returns to stakeholders through cycles.
Negative Factors
Weak revenue growth
Stagnant top-line and a sharp TTM revenue decline signal structural demand challenges in key end markets. Without sustained organic growth, margin gains and cash flow could be harder to maintain long term and the firm may increasingly rely on acquisitions to meet growth targets.
Read all positive and negative factors
Positive Factors
Negative Factors
Cash generation & conversion
Sustained strong operating and free cash flow gives AddLife durable self-funding capacity for capex, working-capital cushions and bolt-on M&A without heavy equity issuance. High cash conversion also supports deleveraging and returns to stakeholders through cycles.
Read all positive factors
AddLife AB (ALIF.B) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr17.43B
Dividend Yield0.46%
Average Volume (3M)97.37K
Price to Earnings (P/E)34.6
Beta (1Y)0.71
Revenue Growth-0.32%
EPS Growth83.82%
CountrySE
Employees2,251
SectorHealthcare
Sector Strength45
IndustryMedical - Instruments & Supplies
Share Statistics
EPS (TTM)1.05
Shares Outstanding117,877,460
10 Day Avg. Volume108,367
30 Day Avg. Volume97,373
Financial Highlights & Ratios
PEG Ratio0.28
Price to Book (P/B)3.56
Price to Sales (P/S)1.86
P/FCF Ratio17.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr165.00Price Target Upside6.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)6.06
Revenue Forecast (FY)kr10.81B
AddLife AB Business Overview & Revenue Model
Company Description
AddLife AB (publ), together with its subsidiaries, provides equipment, medical devices, and reagents primarily to healthcare system, research, colleges, and universities, as well as the food and pharmaceutical industries. The company operates in t...
How the Company Makes Money
AddLife makes money mainly by distributing and selling life science and healthcare products sourced from third-party manufacturers, complemented by recurring sales of consumables and service-related income. A substantial share of revenue comes fro...
AddLife AB Earnings Call Summary
Earnings Call Date:Feb 04, 2026
(Q4-2025)
| % Change Since: |
Next Earnings Date:Jul 16, 2026
Earnings Call Sentiment Positive
The call conveyed a generally positive tone: clear and continuous margin improvement, strong operating cash flow, meaningful net-debt reduction (net debt-to-EBITDA 2.2), and an active, disciplined M&A pipeline. These positives offset material near-term headwinds from currency effects, some weaker instrument and geographic pockets, and one-off impacts from strikes and a divestment/hand-over of a UK endoscopy business. Management emphasized ongoing margin initiatives, portfolio upgrades and confidence in picking up acquisition activity in 2026.Positive Updates
Improved Profitability and Margins
Adjusted EBITA margin improved to 12.4% in the quarter (vs 12.3% a year ago) and the full-year EBITA margin rose to ~12.1% (up from 11.3% the prior year and 10.5% in 2023). Labtech Q4 margin remained strong at 14.1% and Medtech Q4 margin improved to 12.0% (from 11.6%). Full-year margins: Labtech ~12.5% and Medtech ~12.4%.
Negative Updates
Significant Currency Headwinds
Reported revenue in the quarter was down ~5% (currency headwind) and EBITA was negatively impacted (cited ~7% impact). Including currencies, some reported sales growth was negative (management noted sales growth including currencies was down ~3% in the quarter).
Read all updates
Q4-2025 Updates
Positive
Negative
Improved Profitability and Margins
Adjusted EBITA margin improved to 12.4% in the quarter (vs 12.3% a year ago) and the full-year EBITA margin rose to ~12.1% (up from 11.3% the prior year and 10.5% in 2023). Labtech Q4 margin remained strong at 14.1% and Medtech Q4 margin improved to 12.0% (from 11.6%). Full-year margins: Labtech ~12.5% and Medtech ~12.4%.
Read all positive updates
Company Guidance
Management reiterated guidance to continue the profit-improvement agenda into 2026, aiming to drive further EBITA margin expansion (group FY EBITA 12.1%; Q4 adjusted EBITA 12.4%; Labtech Q4 14.1%/FY 12.5%; Medtech Q4 12.0%/FY 12.4%) while pursuing both organic and M&A-led growth (2025: organic +10%, acquisitions +2%; total EBITA growth 8%). They signalled continued deal activity—having closed Pharmacold and Opitek in December—with a return to a roughly 50/50 organic/acquisition contribution over time and a preferred deal size in the EUR 10–30m turnover range, enabled by a strengthened balance sheet (net debt down ~SEK 900m in 2025 and ~SEK 800m in Q4; net debt/EBITDA 2.2, net debt/adj. EBITA 2.5, target ≤3). Cash generation and working-capital efficiency remain priorities (operating cash flow ~SEK 900m in Q4 and SEK 1.4bn FY; cash conversion 111% FY, 98% excluding disposals, a more realistic ~95% going forward; working-capital release SEK 426m in Q4; inventory/sales 16% vs 17% in 2024), and management reiterated long‑term targets of 15% year‑over‑year profit improvement and profit/working capital above 45% (2025: 62%).AddLife AB Financial Statement Overview
Summary
Income Statement
66
Positive
Balance Sheet
61
Positive
Cash Flow
63
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 10.38B | 10.44B | 10.29B | 9.69B | 9.08B | 7.99B |
| Gross Profit | 3.98B | 3.98B | 3.86B | 3.60B | 3.43B | 2.86B |
| EBITDA | 1.40B | 1.80B | 1.52B | 1.53B | 1.45B | 1.46B |
| Net Income | 568.00M | 560.00M | 252.00M | 190.00M | 480.00M | 719.00M |
Balance Sheet | ||||||
| Total Assets | 13.01B | 12.71B | 13.05B | 12.74B | 13.06B | 10.60B |
| Cash, Cash Equivalents and Short-Term Investments | 771.00M | 813.00M | 331.00M | 272.00M | 376.00M | 345.30M |
| Total Debt | 2.02B | 4.77B | 5.07B | 5.29B | 5.59B | 4.10B |
| Total Liabilities | 7.35B | 7.26B | 7.75B | 7.79B | 8.09B | 6.30B |
| Stockholders Equity | 5.66B | 5.44B | 5.31B | 4.96B | 4.97B | 4.29B |
Cash Flow | ||||||
| Free Cash Flow | 1.12B | 1.14B | 798.00M | 465.00M | 627.00M | 866.30M |
| Operating Cash Flow | 1.26B | 1.39B | 1.09B | 773.00M | 909.00M | 1.01B |
| Investing Cash Flow | -556.00M | -497.00M | -386.00M | -317.00M | -1.09B | -2.98B |
| Financing Cash Flow | -297.00M | -305.00M | -682.00M | -554.00M | 134.00M | 2.07B |
AddLife AB Technical Analysis
Positive
155.10
Price Trends
144.52
Positive
153.74
Positive
167.52
Negative
Market Momentum
5.47
Negative
77.29
Negative
97.22
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ALIF.B, the sentiment is Positive. The current price of 155.1 is above the 20-day moving average (MA) of 145.70, above the 50-day MA of 144.52, and below the 200-day MA of 167.52, indicating a neutral trend. The MACD of 5.47 indicates Negative momentum. The RSI at 77.29 is Negative, neither overbought nor oversold. The STOCH value of 97.22 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:ALIF.B.
AddLife AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | kr14.53B | 60.12 | 19.59% | ― | 21.78% | 51.16% | |
69 Neutral | kr15.83B | 46.90 | 4.54% | ― | 6.11% | 79.07% | |
61 Neutral | kr17.43B | 34.62 | 7.24% | 0.46% | -0.32% | 83.82% | |
58 Neutral | kr14.18B | 31.59 | 3.34% | 0.80% | -5.68% | -1106.19% | |
56 Neutral | kr1.18B | -74.03 | -4.20% | ― | 23.85% | -135.36% | |
54 Neutral | kr20.35B | 546.38 | 3.08% | 4.25% | -4.32% | -103.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
SE:ALIF.B
AddLife AB
142.90
-45.35
-24.09%
SE:EKTA.B
Elekta AB
53.25
5.45
11.41%
SE:VITR
Vitrolife AB
104.70
-50.00
-32.32%
SE:BONEX
BONESUPPORT HOLDING AB
220.60
-89.40
-28.84%
SE:PAX
Paxman AB
50.60
-25.00
-33.07%
SE:VIMIAN
Vimian Group AB
30.10
-8.42
-21.86%
AddLife AB Corporate Events
AddLife Maintains High Margins and Speeds Up Deal-Making as 2026 Begins
Apr 28, 2026
AddLife opened 2026 with slightly lower reported sales but sustained strong profitability, as first-quarter net sales fell 2 percent to SEK 2,645 million while the EBITA margin held at 12.5 percent and profit after tax rose 7 percent. Adjusted for...
AddLife strengthens coagulation diagnostics portfolio with CoaChrom acquisition
Apr 23, 2026
AddLife AB has acquired CoaChrom Diagnostica GmbH, an Austrian specialist in advanced coagulation diagnostics for clinical laboratories and the pharmaceutical industry, with around EUR 10 million in sales and 10 employees. CoaChrom, known for its ...
AddLife Publishes Comprehensive 2025 Annual Report Covering Strategy, Governance and Sustainability
Apr 1, 2026
AddLife AB has published its 2025 Annual Report, providing a comprehensive overview of its operations, strategy, governance, financial performance, and sustainability work. The report covers the company’s market environment, acquisition acti...
AddLife Calls 2026 AGM With Incentive Plan and Share Issue Mandates on Agenda
Mar 30, 2026
AddLife AB has called its Annual General Meeting for 6 May 2026 at the World Trade Center in Stockholm, setting out formal procedures for shareholders to register, attend and exercise their voting rights. Shareholders must be recorded in Euroclear...
AddLife boosts UK medtech footprint with acquisition of BioSpectrum
Mar 12, 2026
AddLife AB has expanded its Medtech business area by acquiring UK-based BioSpectrum Ltd, a fast-growing distributor of surgical solutions in urology, gynaecology and general surgery. BioSpectrum, headquartered in Newark, generates about GBP 6 mill...
AddLife boosts margins and cash flow to fuel renewed acquisition push
Feb 4, 2026
AddLife’s fourth-quarter report shows resilient profitability despite a 3% sales dip, with EBITA margin climbing to 18.2% driven by efficiency gains, portfolio refinements, and two small acquisitions; full-year figures reflect modest 2% net ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.